Novartis AG (NVS)
| Previous close | 101.54 |
| Open | 99.92 |
| Bid | 99.39 x 1200 |
| Ask | 99.41 x 900 |
| Day's range | 99.20 - 100.28 |
| 52-week range | 74.24 - 105.61 |
| Volume | |
| Avg. volume | 1,320,576 |
| Market cap | 207.575B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 27.68 |
| EPS (TTM) | 3.60 |
| Earnings date | N/A |
| Forward dividend & yield | 3.50 (3.43%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | 117.25 |
- Yahoo Finance Video
The 10 pharma companies participating in Medicare price negotiations
Ten pharmaceutical manufacturers are signing the Inflation Reduction Act's Medicare drug price negotiation program. These companies are Bristol Myers Squibb (BMY), AstraZeneca (AZN), Boehringer Ingelheim, Immunex, Janssen Pharmaceuticals, Pharmacyclics, Merck & Company (MRK), Janssen Biotech, Novartis (NVS), and Novo Nordisk (NVO), according to the Biden administration. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
BloombergNovartis Weighs Selling Assets from Radiopharma Unit
(Bloomberg) -- Novartis AG is considering selling part of radiopharmaceuticals company Advanced Accelerator Applications, people with knowledge of the matter said, as it joins an industry-wide push to cast off low-growth business lines.Most Read from BloombergWhy a US Recession Is Still Likely — and Coming SoonKey Taiwan Tech Firms Helping Huawei With China Chip PlantsAirbnb Is Fundamentally Broken, Its CEO Says. He Plans to Fix It.JPMorgan’s Dimon Predicts 3.5-Day Work Week for Next Generation
ZacksHere's Why Novartis (NVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
